<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529229</url>
  </required_header>
  <id_info>
    <org_study_id>DPREMS1111</org_study_id>
    <nct_id>NCT01529229</nct_id>
  </id_info>
  <brief_title>Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment</brief_title>
  <official_title>A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Moderate - Severe Persistent Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the non-inferiority clinical efficacy of two
      different drug associations in the treatment of Moderate - Severe Persistent Allergic
      Rhinitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  double-blind, non-inferiority, prospective, parallel group trial.

        -  Experiment duration: 07 days.

        -  02 visits (days 0 and 7).

        -  Efficacy will be evaluated for persistent allergic rhinitis based on nasal symptoms
           score

        -  Adverse events evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of treatment in persistent allergic rhinitis based on nasal symptoms score</measure>
    <time_frame>7 days</time_frame>
    <description>The mean variability of nasal symptoms score observed between visit 1 and visit 2 will be used as the primary endpoint of clinical efficacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by the adverse events occurrences</measure>
    <time_frame>7 days</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Desloratadine + Prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desloratadine(0.5 mg/ml) Associated With Prednisolone (4 mg/ml) Oral Solution once a day - bottle 1 + placebo 2 times a day - bottles 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexchlorpheniramine + Betamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexchlorpheniramine (0.4 mg/ml) + Betamethasone (0.05 mg/ml) three times a day - bottles 1, 2 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexchlorpheniramine + Betamethasone</intervention_name>
    <description>Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day</description>
    <arm_group_label>Dexchlorpheniramine + Betamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine + Prednisolone</intervention_name>
    <description>Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day</description>
    <arm_group_label>Desloratadine + Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consent of the patient or legal guardian;

          -  Clinical diagnosis of moderate - severe persistent allergic rhinitis according to the
             classification of ARIA (Allergic Rhinitis and Its Impact on Asthma);

          -  Children aged between 2 and 11 years and 11 months (up to 30 kg);

          -  Presence of nasal symptoms score greater than or equal to 5 (scale 0 to 12)in the last
             week;

          -  Evidence of sensitization to aeroallergens in examination (immediate skin tests or
             serum specific IgE) in the 12 months prior to inclusion.

        Exclusion Criteria:

          -  Participation in clinical trial in 30 days prior to study entry;

          -  Patients receiving immunotherapy;

          -  Patients with history of hypersensitivity to desloratadine or prednisolone or with
             corticosteroids use contraindications ;

          -  Patients with any clinically significant disease other than allergic rhinitis,
             including hematopoietic, cardiovascular, renal, neurological, psychiatric or
             autoimmune disorders;

          -  Patients on treatment with monoamine oxidase inhibitors (MAOIs);

          -  Patients who were in use of oral antihistamines or decongestants in the past 15 days;

          -  Patients who were treated with systemic corticosteroids in the last month;

          -  Patients who have uncontrolled asthma, chronic sinusitis, drug related rhinitis and
             nasal anatomic abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirceu Solé, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <last_update_submitted>January 14, 2015</last_update_submitted>
  <last_update_submitted_qc>January 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
    <mesh_term>Dexchlorpheniramine</mesh_term>
    <mesh_term>Chlorpheniramine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 25, 2015</submitted>
    <returned>September 25, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

